It’s Technology Transfer Gameday, What’s Your Strategy? How are you Getting to Patients Faster while Maintaining Quality?

For 40 years Pfizer CentreOne has been guiding drug projects to success. Here’s how our services make us an altogether different kind of CDMO: 

Welcome to Pfizer CentreOne. We’re a global CDMO embedded within Pfizer and a leading supplier of specialty APIs. Working with our customers, we combine our technical and commercial knowledge with open dialogue to solve challenges – we call this intelligent collaboration.

Partner with creative scientists and problem-solvers dedicated to making your drug development journey a success. 

Getting drugs to market faster and more economically is prompting new drug product development strategies to support better business and patient outcomes. Development of critical drug substances, particularly novel small molecule active pharmaceutical ingredients (APIs), is now being turned over to outsourced partners who have become the integral, primary drivers of the product’s overall development and go-to-market strategy.

Understanding the complexity of HPAPI transfers is critical to successful commercialization. How should CDMO partnerships approach the challenges of HPAPI technology transfer to reach patients successfully? Kieran Coffey, Technical Services Lead at Pfizer CentreOne, discusses key considerations on this critical collaboration.

As more and more pharma companies look to contract manufacturers for technical expertise, commercial knowledge and specialized technologies to bring their products to market, the CDMO market is more crucial than ever before in advancing the pharma industry. In a crowded marketplace, choosing the right manufacturing partner for your product is key. This webinar will examine the latest trends and developments in the large and small molecule CDMO space – from manufacturing complex products at scale, to acquiring talent and technology to future-proof Pharma.

Pfizer and BioNTech’s shot on Monday became the first COVID-19 vaccine to be granted full approval by the US Food and Drug Administration.

Talk of bringing back domestic manufacturing to North America has dominated conversations around pharma manufacturing for years, and have been a key talking point in government post-pandemic recovery plans, but how far have we come and who is this really working for? Asian CDMO’s recognizing the trend for western domestic production are globalizing their operations. Will there be an increase in the Civica Rx business model? This session broadcast was a part of CPHI North America Show

Outsourcing drug manufacturing is a common solution to building manufacturing capacity among drug sponsors. Developing appropriate oversight for CDMO’s is key to a successful product launch. This session will discuss key responsibilities for drug sponsors in overseeing their providers, including which responsibilities can be delegated and when. We will also explore best practices in obtaining optimum performance and adjusting oversight as necessary to reduce overall program risk. This session was broadcast as part of CPHI NA show.

Q&A featuring Raman Sehgal, host of Molecule to Market and Stephanie Watson, Global Strategy and Commercial Planning Lead at Pfizer CentreOne Diving into the biggest challenges the supply chain are currently facing, as well as potential solutions Dissect successful responses and shed light on the future trends we should all be preparing for. This session was broadcast as part of the CPHI North America show.

Pfizer’s manufacturing excellence story can be likened to the sport of crew rowing. Eight people, literally rowing in the same direction in unison. Multiple efforts, focus and strengths are combined in the pursuit of a common goal. It takes precise choreography, teamwork and a common understanding of the manner in which results can and should be achieved.
“The power of the team is unlocked as each rower works in harmony, adding their power to the whole. When everyone buys in and commits to the system, great things can be achieved.”
IMEx (Integrated Manufacturing Excellence) is Pfizer’s production system that mandates a common way of working, applies that at all levels, globally and rewards individuals, teams and facilities on their outcomes. The advantages and success of IMEx are shown clearly in increased speed to patients. That’s the focal point of what Pfizer does and a tool like IMEx is important because it supports that global goal.
But how do we apply it to our CDMO business? How do we leverage such a powerful tool to create the same value for our clients? How does the coxswain and team, working together, create harmony with a supply chain that isn’t entirely our own?
Answering these questions are the crux of this presentation.